442 related articles for article (PubMed ID: 2548710)
1. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.
Hsiang YH; Lihou MG; Liu LF
Cancer Res; 1989 Sep; 49(18):5077-82. PubMed ID: 2548710
[TBL] [Abstract][Full Text] [Related]
2. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system.
Tsao YP; Russo A; Nyamuswa G; Silber R; Liu LF
Cancer Res; 1993 Dec; 53(24):5908-14. PubMed ID: 8261402
[TBL] [Abstract][Full Text] [Related]
3. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
Holm C; Covey JM; Kerrigan D; Pommier Y
Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
[TBL] [Abstract][Full Text] [Related]
4. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.
Hsiang YH; Liu LF
Cancer Res; 1988 Apr; 48(7):1722-6. PubMed ID: 2832051
[TBL] [Abstract][Full Text] [Related]
5. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues.
Hsiang YH; Liu LF; Wall ME; Wani MC; Nicholas AW; Manikumar G; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Aug; 49(16):4385-9. PubMed ID: 2545341
[TBL] [Abstract][Full Text] [Related]
6. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ
Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase inhibitors can selectively interfere with different stages of simian virus 40 DNA replication.
Snapka RM
NCI Monogr; 1987; (4):55-60. PubMed ID: 2819732
[TBL] [Abstract][Full Text] [Related]
8. SV40 DNA replication intermediates: analysis of drugs which target mammalian DNA replication.
Snapka RM; Permana PA
Bioessays; 1993 Feb; 15(2):121-7. PubMed ID: 8385943
[TBL] [Abstract][Full Text] [Related]
9. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B.
Tsao YP; D'Arpa P; Liu LF
Cancer Res; 1992 Apr; 52(7):1823-9. PubMed ID: 1312900
[TBL] [Abstract][Full Text] [Related]
10. Replication-dependent and -independent camptothecin cytotoxicity of seven human colon tumor cell lines.
Borovitskaya AE; D'Arpa P
Oncol Res; 1998; 10(5):271-6. PubMed ID: 9802062
[TBL] [Abstract][Full Text] [Related]
11. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.
Goldwasser F; Shimizu T; Jackman J; Hoki Y; O'Connor PM; Kohn KW; Pommier Y
Cancer Res; 1996 Oct; 56(19):4430-7. PubMed ID: 8813137
[TBL] [Abstract][Full Text] [Related]
12. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
13. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks.
Avemann K; Knippers R; Koller T; Sogo JM
Mol Cell Biol; 1988 Aug; 8(8):3026-34. PubMed ID: 2850477
[TBL] [Abstract][Full Text] [Related]
14. Contribution of gene-specific lesions, DNA-replication-associated damage, and subsequent transcriptional inhibition in topoisomerase inhibitor-mediated apoptosis in lymphoma cells.
Muscarella DE; Rachlinski MK; Sotiriadis J; Bloom SE
Exp Cell Res; 1998 Jan; 238(1):155-67. PubMed ID: 9457068
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
16. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells.
Mattern MR; Mong SM; Bartus HF; Mirabelli CK; Crooke ST; Johnson RK
Cancer Res; 1987 Apr; 47(7):1793-8. PubMed ID: 3028614
[TBL] [Abstract][Full Text] [Related]
18. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
Emerson DL; Besterman JM; Brown HR; Evans MG; Leitner PP; Luzzio MJ; Shaffer JE; Sternbach DD; Uehling D; Vuong A
Cancer Res; 1995 Feb; 55(3):603-9. PubMed ID: 7834631
[TBL] [Abstract][Full Text] [Related]
19. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
20. Exposure to camptothecin breaks leading and lagging strand simian virus 40 DNA replication forks.
Shin CG; Snapka RM
Biochem Biophys Res Commun; 1990 Apr; 168(1):135-40. PubMed ID: 2158312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
